Home › Liver Cancer (Hepatocellular Carcinoma) › Missouri
Liver Cancer (Hepatocellular Carcinoma) clinical trials in Missouri
14 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in Missouri.
Cities in Missouri
The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Oct 5, 2026 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Siteman Cancer Center - St. Peters, City of Saint Peters
- Siteman Cancer Center - West County, Creve Coeur
- Siteman Cancer Center - North County, Florissant
- and 6 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07227012A Study Evaluating a New Radiation Treatment Workflow (NGDS)
- Siteman Cancer Center Washington University, St Louis
Recruiting
Ages 21 and older · All sexes · Updated Sep 17, 2026 · NCT07824583Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Washington University School of Medicine, St Louis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Washington University School of Medicine, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07166406First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT06795022IDOV-Immune for Advanced Solid Tumors
- Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06910657A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Mosaic Life Care at Saint Joseph - Medical Center, Saint Joseph
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO, St Louis
Recruiting
Ages 18 to 75 · All sexes · Updated Jun 17, 2026 · NCT05486572A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Washington University in St. Louis, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 27, 2026 · NCT05440708SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Kansas City
- Massive Bio SYNERGY-AI site, St Louis
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.